Zenas BioPharma shares fall after Phase 3 obexelimab data in IgG4-RD showed a 56% flare risk reduction, as investors weigh ...

AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the management of fibromyalgia. Esreboxetine is the SS-enantiomer of racemic reboxetine.

When drinking water, glass and copper bottles are two popular choices. Copper water bottles contain antimicrobial properties, ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

Johnson & Johnson announces positive results from phase 3 MajesTEC-9 study of Tecvayli in patients with multiple myeloma ...

The hiking trails surrounding Mt. Baldy reopened to visitors Wednesday after being closed due to winter storms and three ...

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...

QPR3 Beta 2 is now available for Pixel devices, bringing critical fixes for battery drain, Wi-Fi connectivity, charging ...

Paper: Doctors Should Screen For ‘Problematic Chatbot Use’ As New Mental Health Risk Factor In A Nutshell One in ten ...

It wasn't exactly a surprise after months of leaks and speculation, but Nvidia CEO Jensen Huang (in perhaps his finest ...

At the moment, Gemini’s “Computer Use” efforts are focused on desktop web as seen by the Gemini Agent available ...

CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data ...